Solid Biosciences SLDB
NASDAQ SLDB
$10.35 -0.07 (-0.69%)
As of: Sep 4, 2026 · 3:12 PM EDT

Solid Biosciences (SLDB) Non Operating Interest Expenses (2023 - 2025)

Analysis

Solid Biosciences (SLDB) Non Operating Interest Expenses (2023 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Solid Biosciences 1.49 Bn 1.49 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 5,000.00
Sep 30, 2025 -336,000.00
Jun 30, 2025 60,000.00
Mar 31, 2025 68,000.00
Dec 31, 2024 75,000.00
Sep 30, 2024 82,000.00
Jun 30, 2024 88,000.00
Mar 31, 2024 95,000.00
Dec 31, 2023 101,000.00
Sep 30, 2023 106,000.00
Jun 30, 2023 111,000.00
Mar 31, 2023 121,000.00